Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
P/B ratio for Embecta Corp. (EMBC)
P/B ratio as of 2023: -1.05
According to Embecta Corp.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -1.05. At the end of 2022 the company had a P/B ratio of -1.84.
P/B ratio history for Embecta Corp. from 2019 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | -1.05 |
| 2022 | -1.84 |
| 2021 | 4.49 |
| 2020 | 4.68 |
| 2019 | 4.64 |